This Diagnostic Startup Uses Saliva to Detect Oral Diseases Earlier

For years, clinical studies have shown a correlation between things like gum disease and chronic conditions such as cardiovascular disease. Oral Genome, a member of the Health Wildcatters accelerator, is a healthcare startup that’s developing saliva tests to detect and prevent oral diseases. In response to emailed questions, Saw talked about her company’s approach.

Why did you start this company?

I started Oral Genome to address a significant gap in the early detection and prevention of oral diseases, particularly focusing on how these diseases are linked to systemic health issues like diabetes. The goal was to create a product that not only improves individual health outcomes but also promotes health equity on a global scale by making advanced saliva testing accessible to all.

What need are you seeking to address in healthcare?

Oral Genome seeks to address the need for early detection and personalized prevention of oral diseases. Our tests provide insights into risks for cavities, gum disease, and diabetes, empowering patients and healthcare providers to take proactive measures. This not only improves individual health outcomes but also reduces healthcare costs associated with untreated oral and systemic conditions.

What does your product do? How does it work?

Oral Genome provides saliva testing kits that analyze specific biomarkers related to oral and systemic health, such as MMP-8, an early marker for periodontal disease. The tests can be used at home or in clinical settings, providing personalized reports that help in risk stratification and targeted interventions. The product bridges the gap between oral health and overall wellbeing, making it easier for healthcare providers to diagnose and manage patients’ health proactively.

Is this your first healthcare startup? What’s your background in healthcare?

This is not my first venture in healthcare; I have extensive experience in the dental field as a practicing dentist. My background includes building a successful dental practice and co-founding companies focused on innovative solutions in oral health. Oral Genome represents a culmination of my experience and passion for improving health outcomes through cutting-edge biotechnology.

What is your company’s business model?

Oral Genome operates on a B2B model, partnering with dental practices, public health organizations, and insurance companies to offer our diagnostic tests. We are also expanding into direct-to-consumer sales, allowing individuals to purchase our kits online for personal use. Our business model includes one-time purchases, value-added online services and potential insurance reimbursements.

Who is your customer?

Our primary customers are dental and medical practices, public health organizations, and insurance companies. We also target individual consumers who are proactive about their health and want to take advantage of the insights provided by our tests. Additionally, we work with partners who focus on underserved communities to improve health equity.

How do you generate revenue? 

We generate revenue through the sale of our saliva testing kits to both B2B clients and direct consumers. We are in the midst of launching additional revenue streams that will drive value to a home consumer.

Do you have clinical validation for your product?

Yes, Oral Genome has completed clinical and lab validation, demonstrating that our product works effectively and has good predictability for dental health outcomes. During this process, we observed direct correlations between oral diseases and the results from our saliva tests, further validating the accuracy and relevance of our product in managing oral health.

At what stage of development is your lead product?

Our lead product, the Oral Genome saliva testing kit, is fully developed and available on the market. We have successfully launched it and are in the process of scaling up our operations and expanding our market reach.

Photo: Zametelov, Getty Images